It supports normal nerve function and energy metabolism, and is commonly prescribed in vitamin B deficiency states and certain cases of neuropathy associated with nutritional deficiency
PMID: 40756949 (view on PubMed) Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disabled Myotendinous Junctions in Rats
BPC-157 is not approved by Health Canada for any therapeutic indication
Potential benefits include: Improved insulin sensitivity Increased metabolic flexibility Enhanced exercise endurance Better glucose regulation By optimizing cellular energy production, MOTS-C helps create an environment where fat loss becomes more achievable and sustainable
Strong candidates include: Patients who have experienced significant nausea on standalone semaglutide and want a formulation that may improve tolerability
Description Additional information Review Description BPC-157 5mg is a research-use-only laboratory material supplied for controlled research workflows, compound characterization, and analytical documentation review
